Shots: The breakthrough designation is based on P-II GALAHAD study assessing Niraparib in adult patients with BRCA1/2 gene-mCRPC and DNA-repair gene defects (DRD) prior treated with androgen-receptor targeting therapies and […]readmore
Tags : Metastatic Castration-Resistant Prostate Cancer
Shots: The P-III PROfound study involves assessing of Lynparza (olaparib) vs Enzalutamide/Abiraterone in men with mCRPC and have progressed on prior treatment with anti-cancer therapies with HRRm gene mutation The […]readmore
Shots: Arvinas’ ARV-110 is an orally available PROTAC protein degrader used for targeting androgen receptor (AR) protein and is currently evaluated in P-I for its safety, tolerability, and PK in […]readmore
Shots: The P-II CheckMate -650 trial involves assessing of Opdivo (nivolumab, 1mg/kg) + Yervoy (ipilimumab, 3mg/kg) in patients with mCRPC P-II study result in asymptomatic or minimally symptomatic patients & […]readmore